Roses et al., 2014 - Google Patents
New applications of disease genetics and pharmacogenetics to drug developmentRoses et al., 2014
View HTML- Document ID
- 10434931552332094692
- Author
- Roses A
- Saunders A
- Lutz M
- Zhang N
- Hariri A
- Asin K
- Crenshaw D
- Budur K
- Burns D
- Brannan S
- Publication year
- Publication venue
- Current opinion in pharmacology
External Links
Snippet
Highlights•A variable polyT variation within TOMM40 was associated with MCI-AD.•TOMM40 genotypes are 97% informative for estimating age of onset risk.•TOMMORROW is a Phase III delay of onset of MCI-AD in 65–83 year olds.•Pioglitazone has a large safety experience …
- 230000002974 pharmacogenomic 0 title abstract description 11
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for mutation or polymorphism detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
- G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Roses et al. | New applications of disease genetics and pharmacogenetics to drug development | |
Corbett et al. | Intronic ATTTC repeat expansions in STARD7 in familial adult myoclonic epilepsy linked to chromosome 2 | |
Reitz et al. | Genetic variants in the Fat and Obesity Associated (FTO) gene and risk of Alzheimer's disease | |
Bonder et al. | Genetic and epigenetic regulation of gene expression in fetal and adult human livers | |
Saykin et al. | Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans | |
Hamza et al. | Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease | |
Debette et al. | Genome-wide studies of verbal declarative memory in nondemented older people: the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium | |
Yan et al. | Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia | |
Laje et al. | Genetic markers of suicidal ideation emerging during citalopram treatment of major depression | |
International Headache Genetics Consortium Anttila Verneri verneri. anttila@ sanger. ac. uk 1 2 b Stefansson Hreinn 3 Kallela Mikko 4 Todt Unda 5 6 Terwindt Gisela M 7 Calafato M Stella 1 8 Nyholt Dale R 9 Dimas Antigone S 1 10 11 Freilinger Tobias 12 13 Müller-Myhsok Bertram 14 Artto Ville 4 Inouye Michael 1 15 Alakurtti Kirsi 1 2 Kaunisto Mari A 2 16 Hämäläinen Eija 1 2 de Vries Boukje 15 Stam Anine H 7 Weller Claudia M 15 Heinze Axel 17 Heinze-Kuhn Katja 17 Goebel Ingrid 5 6 Borck Guntram 5 6 Göbel Hartmut 17 Steinberg Stacy 3 Wolf Christiane 14 Björnsson Asgeir 3 Gudmundsson Gretar 18 Kirchmann Malene 19 Hauge Anne 19 Werge Thomas 20 Schoenen Jean 21 Eriksson Johan G 16 22 23 24 Hagen Knut 25 Stovner Lars 25 Wichmann H-Erich 26 27 28 Meitinger Thomas 29 30 Alexander Michael 31 32 Moebus Susanne 33 Schreiber Stefan 34 35 Aulchenko Yurii S 36 Breteler Monique MB 36 Uitterlinden Andre G 37 Hofman Albert 36 van Duijn Cornelia M 36 Tikka-Kleemola Päivi 38 Vepsäläinen Salli 4 Lucae Susanne 14 Tozzi Federica 39 Muglia Pierandrea 39 40 Barrett Jeffrey 1 Kaprio Jaakko 2 24 41 Färkkilä Markus 4 Peltonen Leena 1 2 42 Stefansson Kari 3 Zwart John-Anker 25 43 Ferrari Michel D 7 Olesen Jes 19 Daly Mark 42 Wessman Maija 2 16 van den Maagdenberg Arn MJM 7 15 Dichgans Martin 12 13 Kubisch Christian 5 6 44 45 Dermitzakis Emmanouil T 11 Frants Rune R 15 Palotie Aarno aarno. palotie@ sanger. ac. uk 1 2 42 46 47 bw | Genome-wide association study of migraine implicates a common susceptibility variant on 8q22. 1 | |
Illig et al. | A genome-wide perspective of genetic variation in human metabolism | |
Li et al. | Genome-wide association studies of antidepressant class response and treatment-resistant depression | |
Tan et al. | Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus | |
Mangone et al. | Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations | |
Murphy Jr et al. | BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression | |
Marshe et al. | Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response | |
Lin et al. | Cross-tissue exploration of genetic and epigenetic effects on brain gray matter in schizophrenia | |
Ohi et al. | The SIGMAR1 gene is associated with a risk of schizophrenia and activation of the prefrontal cortex | |
Tammiste et al. | Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression | |
Firouzabadi et al. | Genetic variants of angiotensin-converting enzyme are linked to autism: a case-control study | |
Julià et al. | Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis | |
Engelmann et al. | Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial | |
Liu et al. | Influence of the rs1080985 single nucleotide polymorphism of the CYP2D6 gene and APOE polymorphism on the response to donepezil treatment in patients with Alzheimer's disease in China | |
Grossman et al. | Alzheimer’s disease: diagnostics, prognostics and the road to prevention | |
Mahmoudi et al. | The MIR137 VNTR rs58335419 is associated with cognitive impairment in schizophrenia and altered cortical morphology |